



FEP Medical Policy Manual

FEP 2.01.54 Endovascular Procedures for Intracranial Arterial Disease (Atherosclerosis and Aneurysms)

Effective Policy Date: July 1, 2022

Original Policy Date: December 2011

Related Policies:

7.01.68 - Extracranial Carotid Artery Stenting

Endovascular Procedures for Intracranial Arterial Disease (Atherosclerosis and Aneurysms)

Description

Description

Intracranial arterial disease includes thromboembolic events, vascular stenoses, and aneurysms. Endovascular techniques have been investigated for the treatment of intracranial arterial disease. Endovascular therapy is used as an alternative or adjunct to intravenous tissue plasminogen activator and supportive care for acute stenosis and as an adjunct to risk-factor modification for chronic stenosis. For cerebral aneurysms, stent-assisted coiling and the use of flow-diverting stents have been evaluated as an alternative to endovascular coiling in patients whose anatomy is not amenable to simple coiling.

OBJECTIVE

The objective of this evidence review is to determine whether endovascular therapies improve the net health outcome in patients with acute ischemic stroke, intracranial arterial stenosis, or intracranial aneurysm.

POLICY STATEMENT

Intracranial stent placement may be considered **medically necessary** as part of the endovascular treatment of intracranial aneurysms for patients when surgical treatment is not appropriate and standard endovascular techniques do not allow for complete isolation of the aneurysm, eg, wide-neck aneurysm (≥ 4 mm) or a sack-to-neck ratio less than 2:1.

Intracranial flow-diverting stents with U.S. Food and Drug Administration (FDA) approval for the treatment of intracranial aneurysms may be considered **medically necessary** as part of the endovascular treatment of intracranial aneurysms that meet anatomic criteria (see Policy Guidelines section) and are not amenable to surgical treatment or standard endovascular therapy.

Intracranial stent placement is considered **investigational** in the treatment of intracranial aneurysms except as noted above.

Intracranial percutaneous transluminal angioplasty with or without stenting is considered **investigational** in the treatment of atherosclerotic cerebrovascular disease.

The use of endovascular mechanical embolectomy using a device with FDA approval for the treatment of acute ischemic stroke may be considered **medically necessary** as part of the treatment of acute ischemic stroke for patients who meet all of the following criteria:

Have a demonstrated occlusion within the proximal intracranial anterior circulation (intracranial internal carotid artery, or M1 or M2 segments of the middle cerebral artery, or A1 or A2 segments of the anterior cerebral artery); AND

- Can receive endovascular mechanical embolectomy within 12 hours of symptom onset OR within 24 hours of symptom onset if there is evidence of a mismatch between specific clinical and imaging criteria (see Policy Guidelines); AND
- Have evidence of substantial and clinically significant neurologic deficits (see Policy Guidelines section); AND
- Have evidence of salvageable brain tissue in the affected vascular territory (see Policy Guidelines section); AND
- Have no evidence of intracranial hemorrhage or arterial dissection on computed tomography or magnetic resonance imaging.

Endovascular interventions are considered **investigational** for the treatment of acute ischemic stroke when the above criteria are not met.

POLICY GUIDELINES

Patient Selection for Endovascular Mechanical Embolectomy for Acute Ischemic Stroke

The major randomized controlled trials (RCTs) demonstrating a benefit with endovascular mechanical embolectomy vary in criteria for selecting patients based on the presence or absence of salvageable brain tissue. Several RCTs use the Alberta Stroke Program Early Computed Tomography Score, which is a 10-point quantitative computed tomography (CT) score to assess the presence of early ischemic changes. MR CLEAN (Endovascular treatment for acute ischemic stroke in the Netherlands) (Berkhemer et al, 2015) did not specify imaging criteria to demonstrate salvageable brain tissue.¹ Table PG1 lists the criteria used by other trials.

Table PG1. Trial Selection Criteria for Salvageable Brain Tissue

Trial	Inclusion or Exclusion	Criteria
REVASCAT (Jovin et al, 2015) ²	Exclusion	Hypodensity on CT or restricted diffusion demonstrated by: <ul style="list-style-type: none"> • An ASPECTS <7 on CT, CT perfusion CBV, CTA source imaging; OR • An ASPECTS <6 on DWI MRI
ESCAPE (Goyal et al, 2015) ³	Exclusion	Baseline non-contrast CT with extensive early ischemic changes of ASPECTS of 0-5 in the territory of symptomatic intracranial occlusion; OR other confirmation of a moderate-to-large core defined 1 of 3 ways: <ul style="list-style-type: none"> • On a single-phase, multiphase, or dynamic CTA: no or minimal collaterals in a region greater than 50% of the MCA territory when compared with pial filling on

		<ul style="list-style-type: none"> the contralateral side (multiphase/dynamic CTA preferred); OR On CT perfusion (>8 cm coverage): a low CBV and very low CBF, ASPECTS <6 AND in the symptomatic MCA territory; OR On CT perfusion (<8 cm coverage): a region of low CBV and very low CBF greater than one-third of the CT perfusion-imaged symptomatic MCA territory
EXTEND-IA (Campbell et al, 2015) ⁴ ,	Inclusion	Based on CT perfusion imaging using CT or MRI with a Tmax more than 6-s delay perfusion volume and either CT regional CBF or DWI infarct core volume as follows: Mismatch ratio >1.2; AND Absolute mismatch volume >10 mL; AND Infarct core lesion volume <70 mL
SWIFT-PRIME (Saver et al, 2015) ⁵ ,	Exclusion	Related to imaging-demonstrated core infarct and hypoperfusion: MRI-assessed core infarct lesion greater than: 50 cm ³ for subjects age 18-79 y; 20 cm ³ for subjects age 80-85 y CT-assessed core infarct lesion greater than: 40 cm ³ for subjects age 18-79 y; 15 cm ³ for subjects age 80-85 y For all subjects, severe hypoperfusion lesion (10-s Tmax lesion >100 cm ³) For all subjects, ischemic penumbra of ≥15 cm ³ and mismatch ratio >1.8

ASPECTS: Alberta Stroke Program Early Computed Tomography Score; CBF: cerebral blood flow; CBV: cerebral blood volume; CT: computed tomography; CTA: computed tomography angiography; DWI: diffusion-weighted imaging; ESCAPE: Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke; EXTEND-IA: Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra-Arterial; MCA: middle cerebral artery; MRI: magnetic resonance imaging;

REVASCAT: Endovascular Revascularization With Solitaire Device Versus Best Medical Therapy in Anterior Circulation Stroke Within 8 Hours; SWIFT PRIME: Solitaire With the Intention For Thrombectomy as PRIMary Endovascular Treatment

The RCTs demonstrating a benefit to endovascular mechanical embolectomy in acute stroke generally had some inclusion criteria to reflect stroke severity with the exception of the EXTEND-IA (Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra-Arterial) trial.⁴ The REVASCAT (Endovascular Revascularization With Solitaire Device Versus Best Medical Therapy in Anterior Circulation Stroke Within 8 Hours) and ESCAPE (Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke) trials both required a baseline (poststroke) National Institutes of Health Stroke Scale score of 6 or higher.^{2,3} MR CLEAN specified a clinical diagnosis of acute stroke with a deficit on the National Institutes of Health Stroke Scale score of 2 points or more¹; SWIFT-PRIME (Solitaire With the Intention For Thrombectomy as PRIMary Endovascular Treatment) specified a National Institutes of Health Stroke Scale score of 8 or more and less than 30 at the time of randomization.⁵

The DAWN (Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention With Trevo) and DEFUSE 3 (Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3) studies enrolled patients from 6 up to 24 hours of the time last time known to be well if there was evidence of a mismatch between specific clinical and imaging criteria (infarct size and volume was assessed with the use of diffusion-weighted magnetic resonance imaging or perfusion CT) (see Table PG2).^{6,7}

Table PG2. Trial Selection Criteria for Patients 6 to 25 Hours Post Infarct

Trial	Inclusion or Exclusion	Criteria
DAWN Trial (Nogueira et al, 2018) ⁶ ,	Inclusion	6 to 24 hours related to mismatch between severity of clinical deficit and infarct volume: ≥80 years of age, score ≥10 on the NIHSS, and had an infarct volume <21 mL; OR ≤80 years age, score of ≥10 on the NIHSS, and had an infarct volume <31 mL; OR ≤80 years of age, had a score ≥20 on the NIHSS, and had an infarct volume of 31 to <51 mL
DEFUSE 3 Trial (Albers et al, 2018) ⁷ ,	Inclusion	6 to 16 hours related to mismatch between severity of clinical deficit and infarct volume: Infarct size of <70 mL; AND ratio of ischemic tissue volume to infarct volume of ≥1.8; AND ischemic penumbra of ≥15 cm ³

DAWN: Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention With Trevo; DEFUSE 3: Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3; NIHSS: National Institutes of Health Stroke Scale.

Other Policy Guidelines

Flow-diverting stents are indicated for the treatment of large or giant wide-necked intracranial aneurysms, with a size of 10 mm or more and a neck diameter of 4 mm or more, in the internal carotid artery from the petrous to the superior hypophyseal segments.

This policy only addresses endovascular therapies used on intracranial vessels.

These policy statements are not intended to address the use of rescue endovascular therapies, including intra-arterial vasodilator infusion and intracranial percutaneous transluminal angiography, in delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.

BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

FDA REGULATORY STATUS

Several devices for endovascular treatment of intracranial arterial disease were cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process or the humanitarian device exemption process. By indication, approved devices are as follows.

Acute Stroke

Table 1 summarizes the first generation devices with FDA clearance for the endovascular treatment of acute stroke and subsequent approval of stent retrievers.

Table 1. Food and Drug Administration-Cleared Mechanical Embolectomy Devices for Acute Stroke

Device	510(k) No. for Original Device	Approval Date for Original Device	Indications
Esperance™ Aspiration Catheter System (Wallaby Medical)	K211697	Nov 2021	Patients with acute ischemic stroke within 8 h of symptom onset who are ineligible for or who fail IV t-PA
Embotrap III Revascularization Device (Neuravi Ltd)	K211338	July 2021	Patients with acute ischemic stroke within 8 h of symptom onset who are ineligible for or who fail IV t-PA
ZOOM™ 71 Reperfusion Catheter (Imperative Care, Inc)	K211476	June 2021	Patients with acute ischemic stroke within 8 h of symptom onset who are ineligible for or who fail IV t-PA
ZOOM Reperfusion Catheter (Imperative Care, Inc)	K210996	April 2021	Patients with acute ischemic stroke within 8 h of symptom onset who are ineligible for or who fail IV t-PA
Tigertriever™ and Tigertriever 17 Revascularization Devices (Rapid Medical, Ltd)	K203592	Mar 2021	Patients with acute ischemic stroke within 8 h of symptom onset who are ineligible for or who fail IV t-PA
Merci Retriever (Concentric Medical; acquired by Stryker Neurovascular in 2011)	K033736	Aug 2004 (modified device approved May 2006)	Patients with acute ischemic stroke and who are ineligible for or who fail IV tPA therapy
Penumbra System (Penumbra)	K072718	Dec 2007	Patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease within 8 h of symptom onset
Stent retrievers			

Solitaire™ FR Revascularization Device (Covidien/ev3 Neurovascular)	K113455	Mar 2012	Patients with acute ischemic stroke due to large intracranial vessel occlusion who are ineligible for or who fail IV tPA
Trevo NXT ProVue Retriever (Stryker Neurovascular)	K210502	Aug 2021	Patients with acute ischemic stroke within 6 h of symptom onset who fail IV t-PA; patients with acute ischemic stroke within 8 h of symptom onset who are ineligible for or who fail IV t-PA; patients with smaller core infarcts may start therapy as late as 24 h after last seen well
Trevo Retriever device (Stryker Neurovascular)	K122478	Aug 2012	Patients with acute ischemic stroke due to large intracranial vessel occlusion who are ineligible for or who fail IV tPA
EmboTrap II Revascularization Device	K173452	May 2018	Patients with ischemic stroke within 8 hours of symptom onset who are ineligible for or who fail IV t-PA

IV: intravenous; tPA: tissue plasminogen activator.

Intracranial Arterial Stenosis

Two devices were approved by the FDA through the humanitarian device exemption process for atherosclerotic disease. This form of FDA approval is available for devices used to treat conditions with an incident rate of 4000 or fewer cases per year; the FDA only requires data showing "probable safety and effectiveness." Devices with their labeled indications are as follows.

Neurolink System

"The Neurolink system [Guidant] is indicated for the treatment of patients with recurrent intracranial stroke attributable to atherosclerotic disease refractory to medical therapy in intracranial vessels ranging from 2.5 to 4.5 mm in diameter with $\geq 50\%$ stenosis and that are accessible to the stent system."

Wingspan™ Stent System

"The Wingspan Stent System [Boston Scientific] with Gateway PTA [percutaneous transluminal angioplasty] Balloon Catheter is indicated for use in improving cerebral artery lumen diameter in patients with intracranial atherosclerotic disease, refractory to medical therapy, in intracranial vessels with $\geq 50\%$ stenosis that are accessible to the system."

Intracranial Aneurysms

In 2011, the Pipeline Embolization Device (Covidien/eV3 Neurovascular), an intracranial aneurysm flow-diverter, was approved by the FDA through the premarket approval process (P100018) for the endovascular treatment of adults (≥ 22 years) with large or giant wide-necked intracranial aneurysms in the internal carotid artery from the petrous to the superior hypophyseal segments.¹⁴ Approval was based on the Pipeline for Uncoilable or Failed Aneurysms Study, a single-arm, open-label feasibility study, reported by Becske et al (2013) that included 108 patients, aged 30 to 75 years, with unruptured large and giant wide-necked aneurysms.¹⁵

In 2018, Surpass Streamline Flow Diverter (Stryker Neurovascular) was approved by the FDA through the premarket approval process (P170024) for use in the endovascular treatment of patients (18 years of age and older) with unruptured large or giant saccular wide-neck (neck width ≥ 4 mm or dome-to-neck ratio < 2) or fusiform intracranial aneurysms in the internal carotid artery from the petrous segment to the terminus arising from a parent vessel with a diameter ≥ 2.5 mm and ≤ 5.3 mm. The approval was based on 1 year results of the Surpass Intracranial Aneurysm Embolization System Pivotal Trial to Treat Large or Giant Wide Neck Aneurysms (SCENT) study. The SCENT study is continuing follow-up to 5 years post-procedure as a post-approval study.

The following stents have been approved by the FDA through the humanitarian device exemption process for treatment of intracranial aneurysms.

Neuroform™ Microdelivery Stent System

In 2002, based on a series of approximately 30 patients with 6-month follow-up, the Neuroform Microdelivery Stent System (Stryker) was approved by the FDA through the humanitarian device exemption process (H020002) for use with embolic coils for the treatment of wide-neck intracranial aneurysms that cannot be treated by surgical clipping.

Neuroform™ Atlas Stent System

In 2019, the Neuroform Atlas Stent System (Stryker) was approved by the FDA through the premarket approval process (P190031) based on the pivotal ATLAS study including 201 patients with up to 12 months of follow-up. The approved indication is "for use with neurovascular embolization coils in the anterior circulation of the neurovasculature for the endovascular treatment of patients greater than or equal to 18 years of age with saccular wide-necked (neck width greater or equal to 4 mm or a dome-to-neck ratio of <2) intracranial aneurysms arising from a parent vessel with a diameter of greater than or equal to 2.0 mm and less than or equal to 4.5 mm." Product Code: QCA.

Enterprise™ Vascular Reconstruction Device and Delivery System

In 2007, based on a series of approximately 30 patients with 6-month follow-up, the Enterprise™ Vascular Reconstruction Device and Delivery (Cordis Neurovascular) was approved by the FDA through the humanitarian device exemption process (H060001) for use with embolic coils for the treatment of wide-neck, intracranial, saccular or fusiform aneurysms.

The Low-Profile Visualized Intraluminal Support Device

In 2014, the Low-Profile Visualized Intraluminal Support Device (LVIS™ and LVIS™ Jr.; MicroVention) was approved by the FDA through the humanitarian device exemption process (H130005) for use with embolic coils for the treatment of unruptured, wide-neck (neck, ≥ 4 mm or dome-to-neck ratio, <2), intracranial, saccular aneurysms arising from a parent vessel with a diameter of 2.5 mm or greater and 4.5 mm or smaller. In 2018, the LVIS™ and LVIS™ Jr. were approved through the premarket approval process (P170013).

PulseRider Aneurysm Neck Reconstruction Device

In 2017, the PulseRider Aneurysm Neck Reconstruction Device (Pulsar Vascular, Inc.) was approved by the FDA through the humanitarian device exemption process (H160002) for use with neurovascular embolic coils for treatment of unruptured wide-necked intracranial aneurysms with neck width at least 4 mm or dome to neck ratio greater than 2.

RATIONALE

Summary of Evidence

For individuals who have an acute ischemic stroke due to occlusion of an anterior circulation vessel who receive endovascular mechanical embolectomy, the evidence includes randomized clinical trials (RCTs) comparing endovascular therapy with standard care and systematic reviews of these RCTs. Relevant outcomes are overall survival, morbid events, functional outcomes, and treatment-related mortality and morbidity. From 2013 to 2015, 8 RCTs were published comparing endovascular therapies with noninterventional care for acute stroke in patients with anterior circulation occlusions. Several trials that were ongoing at the time of publication of these 8 RCTs were stopped early, and results with the limited enrollment have been published. Trials published from 2014 to 2015 demonstrated a significant benefit regarding reduced disability at 90 days posttreatment. The trials that demonstrated a benefit for endovascular therapy either exclusively used stent retriever devices or allowed the treating physician to select a device, mostly a stent retriever device, and had high rates of mechanical embolectomy device use in patients randomized to endovascular therapy. Studies that demonstrated a benefit for endovascular therapy required demonstration of a large vessel, anterior circulation occlusion for enrollment. Also, they were characterized by fast time-to-treatment. Not all studies published after 2015 have shown a benefit of endovascular therapy in major clinical outcomes, possibly due to small sample sizes and lack of power to detect differences, but systematic reviews have found significant effects. Two trials published in 2018 demonstrated that it was possible to extend the window for mechanical thrombectomy up to about 24 hours for select patients. To achieve results in real-world settings similar to those in clinical trials, treatment times, clinical protocols, and patient selection criteria should be similar to those in RCTs. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have an acute ischemic stroke due to basilar artery occlusion who receive endovascular mechanical embolectomy, the evidence includes an RCT. Relevant outcomes are overall survival, morbid events, functional outcomes, and treatment-related mortality and morbidity. The RCT was terminated early due to high crossovers and poor recruitment. There was not a statistically significant difference in the proportion of participants with a modified Rankin Scale of 0 to 3 at 90 days or in 90-day mortality rates in the endovascular and standard therapy groups. Additional RCTs are ongoing. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have symptomatic intracranial arterial stenosis who receive intracranial percutaneous transluminal angioplasty with or without stenting, the evidence includes a systematic review and 2 major RCTs. Relevant outcomes are overall survival, symptoms, morbid events, functional outcomes, and treatment-related mortality and morbidity. Both available RCTs have demonstrated no significant benefit with endovascular therapy. In particular, the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial was stopped early due to harms, because the rate of stroke or death at 30 days posttreatment was higher in the endovascular arm, which received percutaneous angioplasty with stenting. Follow-up of SAMMPRIS subjects has demonstrated no long-term benefit from endovascular therapy. Although some nonrandomized studies have suggested a benefit from endovascular therapy, the available evidence from 2 RCTs does not suggest that intracranial percutaneous transluminal angioplasty with or without stenting improves outcomes for individuals with symptomatic intracranial stenosis. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome. T.

For individuals who have intracranial aneurysm(s) who receive endovascular coiling with intracranial stent placement or intracranial placement of a flow-diverting stent, the evidence includes RCTs, several nonrandomized comparative studies, and multiple single-arm studies. Relevant outcomes are overall survival, morbid events, functional outcomes, and treatment-related mortality and morbidity. The available nonrandomized comparative studies have reported occlusion rates for stent-assisted coiling that are similar to or higher than coiling alone and recurrence rates that may be lower than those for coiling alone. For stent-assisted coiling with self-expanding stents, some evidence has also shown that adverse event rates are relatively high, and a nonrandomized comparative trial has reported that mortality is higher with stent-assisted coiling than with coiling alone. For placement of flow-diverting stents, a pragmatic RCT and registry study have compared flow diversion with standard management (observation, coil embolization, or parent vessel occlusion) in patients for whom flow diversion was considered a promising treatment. The pragmatic study was stopped early after crossing a predefined safety boundary when 16% of patients treated with flow diversion were dead or dependent at 3 months or later. Flow diversion was also not as effective as the investigators had hypothesized. A nonrandomized study comparing the flow-diverting stents with endovascular coiling for intracranial aneurysms has demonstrated higher rates of aneurysm obliteration in those treated with the Pipeline endovascular device than those treated with coiling, with similar rates of good clinical outcomes. The evidence does not provide high certainty whether stent-assisted coiling or placement of a flow-diverting stent improves outcomes for patients with intracranial aneurysms because the risk-benefit ratio cannot be adequately defined. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

SUPPLEMENTAL INFORMATION

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in "Supplemental Information" if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

Society of Vascular and Interventional Neurology

In 2016, the Society of Vascular and Interventional Neurology published recommendations on comprehensive stroke center requirements and endovascular stroke systems of care.⁹¹ The recommendations were based on 5 multicenter, prospective, randomized, open-label, blinded endpoint clinical trials that demonstrated the benefits of endovascular therapy with mechanical thrombectomy in acute ischemic strokes with large vessel occlusions. Their recommendation pertinent to this evidence review is:

"Endovascular mechanical thrombectomy, in addition to treatment with IV tPA in eligible patients, is recommended for anterior circulation large vessel occlusion ischemic strokes in patients presenting within 6 h of symptom onset."

American Heart Association and American Stroke Association

In 2018, the American Heart Association and the American Stroke Association (update 2019) published joint guidelines on the early management of patients with acute ischemic stroke.^{92,93} These guidelines included several recommendations relevant to the use of endovascular therapies for acute stroke.

Table 2. Recommendations on Use of Endovascular Therapies to Manage Acute Stroke

Recommendation	COR	LOE
"Mechanical thrombectomy requires the patient to be at an experienced stroke center with rapid access to cerebral angiography, qualified neurointerventionalists, and a comprehensive periprocedural care team. Systems should be designed, executed, and monitored to emphasize expeditious assessment and treatment. Outcomes for all patients should be tracked. Facilities are encouraged to define criteria that can be used to credential individuals who can perform safe and timely intra-arterial revascularization procedures."	I	C
<p>"Patients should receive mechanical thrombectomy with a stent retriever if they meet all the following criteria:</p> <ul style="list-style-type: none"> • "Prestroke mRS score 0 to 1, • Causative occlusion of the internal carotid artery or MCA (M1), • Age ≥18 years, • NIHSS score of ≥6, • ASPECTS of ≥6, and • "Treatment can be initiated (groin puncture) within 6 hours of symptom onset." 	I	A
In selected patients with acute ischemic stroke within 6 to 16 hours of last known normal who have LVO in the anterior circulation and meet other DAWN or DEFUSE 3 eligibility criteria, mechanical thrombectomy is recommended.	I	A
"The technical goal of the thrombectomy procedure should be a reperfusion to a modified TIC1 2b/3 angiographic result to maximize the probability of a good functional clinical outcome."	I	A
As with intravenous alteplase, reduced time from symptom onset to reperfusion with endovascular therapies is highly associated with better clinical outcomes. To ensure benefit, reperfusion to TIC1 grade 2b/3 should be achieved as early as possible and within the therapeutic window."	I	B-R
"Use of stent retrievers is indicated in preference to the MERCI device. The use of mechanical thrombectomy devices other than stent retrievers may be reasonable in some circumstances."	IIIb	AB-NR
"The use of proximal balloon guide catheter or a large bore distal access catheter rather than a cervical guide catheter alone in conjunction with stent retrievers may be beneficial. Future studies should examine which systems provide the highest recanalization rates with the lowest risk for nontarget embolization."	IIa	C-LD
In selected patients with AIS within 16 to 24 hours of last known normal who have LVO in the anterior circulation and meet other DAWN eligibility criteria, mechanical thrombectomy is reasonable.	IIa	B-R
"In carefully selected patients with anterior circulation occlusion who have contraindications to intravenous r-tPA, endovascular therapy with stent retrievers completed within 6 hours of stroke onset is reasonable. There are inadequate data available at this time to determine the clinical efficacy of endovascular therapy with stent retrievers for those patients whose contraindications are time-based or nontime-based (eg, prior stroke, serious head trauma, hemorrhagic coagulopathy, or receiving anticoagulant medications)."	IIa	C
"Although the benefits are uncertain, use of mechanical thrombectomy with stent retrievers may be reasonable for carefully selected patients with acute ischemic stroke in whom treatment can be initiated (groin puncture) within 6 hours of symptom onset and who have causative occlusion of the M2 or M3 portion of the MCAs."	IIb	B-R
"Although the benefits are uncertain, use of mechanical thrombectomy with stent retrievers may be reasonable for carefully selected patients with acute ischemic stroke in whom treatment can be	IIb	C

initiated (groin puncture) within 6 hours of symptom onset and who have causative occlusion of the anterior cerebral arteries, vertebral arteries, basilar artery, or posterior cerebral arteries.”		
"Although the benefits are uncertain, use of mechanical thrombectomy with stent retrievers may be reasonable for patients with acute ischemic stroke in whom treatment can be initiated (groin puncture) within 6 hours of symptom onset and who have prestroke mRS score of >1, ASPECTS <6, or NIHSS score <6 and causative occlusion of the internal carotid artery or proximal MCA (M1). Additional randomized trial data are needed.”	IIb	B-R
In patients under consideration for mechanical thrombectomy, observation after IV alteplase to assess for clinical response should not be performed.	III	B-R
"Use of salvage technical adjuncts including intra-arterial fibrinolysis may be reasonable to achieve these angiographic results”	IIb	C-LD
"Intra-arterial fibrinolysis initiated within 6 hours of stroke onset in carefully selected patients who have contraindications to the use of intravenous alteplase might be considered, but the consequences are unknown.”	IIb	C-EO

AIS: acute ischemic stroke; ASPECTS: Alberta Stroke Program Early Computed Tomography Score; COR: class of recommendation; **DAWN: Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention With Trevo**; **DEFUSE 3: Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke**; LOE: level of recommendation; LVO: large vessel occlusion; MCA: middle cerebral artery; mRS: modified Rankin Scale; NIHSS: National Institutes of Health Stroke Scale; r-tPA: recombinant tissue plasminogen activator; TICI: Thrombolysis in Cerebral Infarction.

The 2 associations also published joint guidelines on the management of patients with unruptured intracranial aneurysms in 2015.⁹⁴ These guidelines included the following recommendations relevant to the use of endovascular therapies for aneurysms (Table 3).

Table 3. Recommendations on Management of Unruptured Intracranial Aneurysms

Recommendation	COR	LOE
"...coil embolization may be superior to surgical clipping with respect to procedural morbidity and mortality, length of stay, and hospital costs, so it may be reasonable to choose endovascular therapy over surgical clipping in the treatment of select unruptured intracranial aneurysms, particularly in cases for which surgical morbidity is high, such as at the basilar apex and in the elderly”	IIb	B
"Endovascular treatment of unruptured intracranial aneurysms is recommended to be performed at high-volume centers.”	I	B

COR: class of recommendation; LOE: level of recommendation.

U.S. Preventive Services Task Force Recommendations

No **U.S. Preventive Services Task Force (USPSTF)** recommendations for treatment of intracranial arterial disease were identified. The USPSTF has recommended against screening for asymptomatic carotid artery stenosis in the general population.

Medicare National Coverage

A Medicare national coverage determination on intracranial angioplasty and stenting was released by the Centers for Medicare & Medicaid Services in 2008.⁹⁵ This decision was based on a review of available studies at that time, which consisted of several uncontrolled case series. The Centers for Medicare & Medicaid Services review indicated that this evidence was promising and that, while further well-designed randomized controlled trials were needed to confirm whether outcomes were improved, coverage should be allowed. The national coverage determination contained the following coverage determinations:

1. "Medicare coverage for angioplasty and or stenting for symptomatic patients with greater than 70 percent intracranial arterial stenosis; and

2. Medicare coverage for intracranial angioplasty and stenting for other patients within the context of Category B investigational device exemption trials under coverage with evidence development within a registry.”

REFERENCES

1. Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. *N Engl J Med.* Jan 01 2015; 372(1): 11-20. PMID 25517348
2. Jovin TG, Chamorro A, Cobo E, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. *N Engl J Med.* Jun 11 2015; 372(24): 2296-306. PMID 25882510
3. Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. *N Engl J Med.* Mar 12 2015; 372(11): 1019-30. PMID 25671798
4. Campbell BC, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. *N Engl J Med.* Mar 12 2015; 372(11): 1009-18. PMID 25671797
5. Saver JL, Goyal M, Bonafe A, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. *N Engl J Med.* Jun 11 2015; 372(24): 2285-95. PMID 25882376
6. Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. *N Engl J Med.* Jan 04 2018; 378(1): 11-21. PMID 29129157
7. Albers GW, Marks MP, Kemp S, et al. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. *N Engl J Med.* Feb 22 2018; 378(8): 708-718. PMID 29364767
8. U.S. Centers for Disease Control and Prevention. Stroke facts. May 25, 2021. <https://www.cdc.gov/stroke/facts.htm>. Accessed March 8, 2022.
9. Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. *Stroke.* Mar 2007; 38(3): 967-73. PMID 17272772
10. Sheriff F, Xu H, Maud A, et al. Temporal Trends in Racial and Ethnic Disparities in Endovascular Therapy in Acute Ischemic Stroke. *J Am Heart Assoc.* Mar 15 2022; 11(6): e023212. PMID 35229659
11. de Havenon A, Sheth K, Johnston KC, et al. Acute Ischemic Stroke Interventions in the United States and Racial, Socioeconomic, and Geographic Disparities. *Neurology.* Dec 07 2021; 97(23): e2292-e2303. PMID 34649872
12. Kim Y, Sharrief A, Kwak MJ, et al. Underutilization of Endovascular Therapy in Black Patients With Ischemic Stroke: An Analysis of State and Nationwide Cohorts. *Stroke.* Mar 2022; 53(3): 855-863. PMID 35067099
13. Meyers PM, Schumacher HC, Higashida RT, et al. Indications for the performance of intracranial endovascular neurointerventional procedures: a scientific statement from the American Heart Association Council on Cardiovascular Radiology and Intervention, Stroke Council, Council on Cardiovascular Surgery and Anesthesia, Interdisciplinary Council on Peripheral Vascular Disease, and Interdisciplinary Council on Quality of Care and Outcomes Research. *Circulation.* Apr 28 2009; 119(16): 2235-49. PMID 19349327
14. Food and Drug Administration (FDA). Summary of Safety and Effectiveness: Pipeline™ Embolization Device. 2011; https://www.accessdata.fda.gov/cdrh_docs/pdf10/P100018b.pdf. Accessed March 7, 2022.
15. Becske T, Kallmes DF, Saatci I, et al. Pipeline for uncoilable or failed aneurysms: results from a multicenter clinical trial. *Radiology.* Jun 2013; 267(3): 858-68. PMID 23418004
16. Kahles T, Garcia-Esperon C, Zeller S, et al. Mechanical Thrombectomy Using the New ERIC Retrieval Device Is Feasible, Efficient, and Safe in Acute Ischemic Stroke: A Swiss Stroke Center Experience. *AJNR Am J Neuroradiol.* Jan 2016; 37(1): 114-9. PMID 26294644
17. Vizient. Vascular technologies. Coronary, peripheral, and neurovascular devices. Technology watch. 2019. <https://www.vizientinc.com/our-solutions/supply-chain-solutions/tech-watch>. Accessed March 3, 2022.
18. Abruzzo T, Moran C, Blackham KA, et al. Invasive interventional management of post-hemorrhagic cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. *J Neurointerv Surg.* May 2012; 4(3): 169-77. PMID 22374130
19. Dinger MN, Bleck TP, Claude Hemphill J, et al. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference. *Neurocrit Care.* Sep 2011; 15(2): 211-40. PMID 21773873
20. Schwamm LH, Ali SF, Reeves MJ, et al. Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals. *Circ Cardiovasc Qual Outcomes.* Sep 01 2013; 6(5): 543-9. PMID 24046398
21. Bhatia R, Hill MD, Shobha N, et al. Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action. *Stroke.* Oct 2010; 41(10): 2254-8. PMID 20829513
22. Badhiwala JH, Nassiri F, Alhazzani W, et al. Endovascular Thrombectomy for Acute Ischemic Stroke: A Meta-analysis. *JAMA.* Nov 03 2015; 314(17): 1832-43. PMID 26529161
23. Ciccone A, Valvassori L, Nichelatti M, et al. Endovascular treatment for acute ischemic stroke. *N Engl J Med.* Mar 07 2013; 368(10): 904-13. PMID 23387822
24. Kidwell CS, Jahan R, Gornbein J, et al. A trial of imaging selection and endovascular treatment for ischemic stroke. *N Engl J Med.* Mar 07 2013; 368(10): 914-23. PMID 23394476
25. Broderick JP, Palesch YY, Demchuk AM, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. *N Engl J Med.* Mar 07 2013; 368(10): 893-903. PMID 23390923
26. Chen CJ, Ding D, Starke RM, et al. Endovascular vs medical management of acute ischemic stroke. *Neurology.* Dec 01 2015; 85(22): 1980-90. PMID 26537058

27. Roaldsen MB, Jusufovic M, Berge E, et al. Endovascular thrombectomy and intra-arterial interventions for acute ischaemic stroke. *Cochrane Database Syst Rev*. Jun 14 2021; 6: CD007574. PMID 34125952
28. Bush CK, Kurimella D, Cross LJ, et al. Endovascular Treatment with Stent-Retriever Devices for Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials. *PLoS One*. 2016; 11(1): e0147287. PMID 26807742
29. Hong KS, Ko SB, Lee JS, et al. Endovascular Recanalization Therapy in Acute Ischemic Stroke: Updated Meta-analysis of Randomized Controlled Trials. *J Stroke*. Sep 2015; 17(3): 268-81. PMID 26437993
30. Kennedy SA, Baerlocher MO, Baerlocher F, et al. Meta-Analysis of Local Endovascular Therapy for Acute Ischemic Stroke. *J Vasc Interv Radiol*. Mar 2016; 27(3): 307-21.e2. PMID 26803573
31. Grech R, Schembri M, Thornton J. Stent-based thrombectomy versus intravenous tissue plasminogen activator in acute ischaemic stroke: A systematic review and meta-analysis. *Interv Neuroradiol*. Dec 2015; 21(6): 684-90. PMID 26490828
32. Marmagkiolis K, Hakeem A, Cilingiroglu M, et al. Safety and Efficacy of Stent Retrievers for the Management of Acute Ischemic Stroke: Comprehensive Review and Meta-Analysis. *JACC Cardiovasc Interv*. Nov 2015; 8(13): 1758-65. PMID 26476611
33. Touma L, Filion KB, Sterling LH, et al. Stent Retrievers for the Treatment of Acute Ischemic Stroke: A Systematic Review and Meta-analysis of Randomized Clinical Trials. *JAMA Neurol*. Mar 2016; 73(3): 275-81. PMID 26810499
34. Martins SO, Mont'Alverne F, Rebello LC, et al. Thrombectomy for Stroke in the Public Health Care System of Brazil. *N Engl J Med*. Jun 11 2020; 382(24): 2316-2326. PMID 32521133
35. Khoury NN, Darsaut TE, Ghostine J, et al. Endovascular thrombectomy and medical therapy versus medical therapy alone in acute stroke: A randomized care trial. *J Neuroradiol*. Jun 2017; 44(3): 198-202. PMID 28238522
36. Muir KW, Ford GA, Messow CM, et al. Endovascular therapy for acute ischaemic stroke: the Pragmatic Ischaemic Stroke Thrombectomy Evaluation (PISTE) randomised controlled trial. *J Neurol Neurosurg Psychiatry*. Jan 2017; 88(1): 38-44. PMID 27756804
37. Mocco J, Zaidat OO, von Kummer R, et al. Aspiration Thrombectomy After Intravenous Alteplase Versus Intravenous Alteplase Alone. *Stroke*. Sep 2016; 47(9): 2331-8. PMID 27486173
38. Bracad S, Ducrocq X, Mas JL, et al. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial. *Lancet Neurol*. Oct 2016; 15(11): 1138-47. PMID 27567239
39. Tomsick TA, Yeatts SD, Liebeskind DS, et al. Endovascular revascularization results in IMS III: intracranial ICA and M1 occlusions. *J Neurointerv Surg*. Nov 2015; 7(11): 795-802. PMID 25342652
40. Demchuk AM, Goyal M, Yeatts SD, et al. Recanalization and clinical outcome of occlusion sites at baseline CT angiography in the Interventional Management of Stroke III trial. *Radiology*. Oct 2014; 273(1): 202-10. PMID 24895878
41. Tekle WG, Hassan AE, Jadhav AP, et al. Impact of Periprocedural and Technical Factors and Patient Characteristics on Revascularization and Outcome in the DAWN Trial. *Stroke*. Jan 2020; 51(1): 247-253. PMID 31744425
42. Jovin TG, Nogueira RG, Lansberg MG, et al. Thrombectomy for anterior circulation stroke beyond 6 h from time last known well (AURORA): a systematic review and individual patient data meta-analysis. *Lancet*. Jan 15 2022; 399(10321): 249-258. PMID 34774198
43. Saver JL, Jahan R, Levy EI, et al. Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. *Lancet*. Oct 06 2012; 380(9849): 1241-9. PMID 22932715
44. Akins PT, Amar AP, Pakbaz RS, et al. Complications of endovascular treatment for acute stroke in the SWIFT trial with solitaire and Merci devices. *AJNR Am J Neuroradiol*. Mar 2014; 35(3): 524-8. PMID 24029392
45. Nogueira RG, Lutsep HL, Gupta R, et al. Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. *Lancet*. Oct 06 2012; 380(9849): 1231-40. PMID 22932714
46. Saposnik G, Lebovic G, Demchuk A, et al. Added Benefit of Stent Retriever Technology for Acute Ischemic Stroke: A Pooled Analysis of the NINDS tPA, SWIFT, and STAR Trials. *Neurosurgery*. Sep 2015; 77(3): 454-61. PMID 26280825
47. Pereira VM, Gralla J, Davalos A, et al. Prospective, multicenter, single-arm study of mechanical thrombectomy using Solitaire Flow Restoration in acute ischemic stroke. *Stroke*. Oct 2013; 44(10): 2802-7. PMID 23908066
48. Nogueira RG, Frei D, Kirmani JF, et al. Safety and Efficacy of a 3-Dimensional Stent Retriever With Aspiration-Based Thrombectomy vs Aspiration-Based Thrombectomy Alone in Acute Ischemic Stroke Intervention: A Randomized Clinical Trial. *JAMA Neurol*. Mar 01 2018; 75(3): 304-311. PMID 29296999
49. Cao J, Lin H, Lin M, et al. RECO Flow Restoration Device Versus Solitaire FR With the Intention for Thrombectomy Study (REDIRECT): a prospective randomized controlled trial. *J Neurosurg*. Jun 05 2020; 134(5): 1569-1577. PMID 32502991
50. Mattle HP, Arnold M, Lindsberg PJ, et al. Basilar artery occlusion. *Lancet Neurol*. Nov 2011; 10(11): 1002-14. PMID 22014435
51. Schonewille WJ, Wijman CA, Michel P, et al. Treatment and outcomes of acute basilar artery occlusion in the Basilar Artery International Cooperation Study (BASICS): a prospective registry study. *Lancet Neurol*. Aug 2009; 8(8): 724-30. PMID 19577962
52. Liu X, Dai Q, Ye R, et al. Endovascular treatment versus standard medical treatment for vertebrobasilar artery occlusion (BEST): an open-label, randomised controlled trial. *Lancet Neurol*. Feb 2020; 19(2): 115-122. PMID 31831388
53. Bose A, Hartmann M, Henkes H, et al. A novel, self-expanding, nitinol stent in medically refractory intracranial atherosclerotic stenoses: the Wingspan study. *Stroke*. May 2007; 38(5): 1531-7. PMID 17395864
54. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. *N Engl J Med*. Mar 31 2005; 352(13): 1305-16. PMID 15800226
55. EC/IC Bypass Study Group. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial. *N Engl J Med*. Nov 07 1985; 313(19): 1191-200. PMID 2865674
56. Wang T, Luo J, Wang X, et al. Endovascular therapy versus medical treatment for symptomatic intracranial artery stenosis. *Cochrane Database Syst Rev*. Aug 11 2020; 8: CD013267. PMID 32789891
57. Zaidat OO, Fitzsimmons BF, Woodward BK, et al. Effect of a balloon-expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the VISSIT randomized clinical trial. *JAMA*. Mar 2015; 313(12): 1240-8. PMID 25803346

58. Chimowitz MI, Lynn MJ, Derdeyn CP, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. *N Engl J Med*. Sep 15 2011; 365(11): 993-1003. PMID 21899409
59. Derdeyn CP, Chimowitz MI, Lynn MJ, et al. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. *Lancet*. Jan 25 2014; 383(9914): 333-41. PMID 24168957
60. Lutsep HL, Barnwell SL, Larsen DT, et al. Outcome in patients previously on antithrombotic therapy in the SAMMPRIS trial: subgroup analysis. *Stroke*. Mar 2015; 46(3): 775-9. PMID 25593135
61. Lutsep HL, Lynn MJ, Cotsonis GA, et al. Does the Stenting Versus Aggressive Medical Therapy Trial Support Stenting for Subgroups With Intracranial Stenosis?. *Stroke*. Nov 2015; 46(11): 3282-4. PMID 26382173
62. Coward LJ, McCabe DJ, Ederle J, et al. Long-term outcome after angioplasty and stenting for symptomatic vertebral artery stenosis compared with medical treatment in the Carotid And Vertebral Artery Transluminal Angioplasty Study (CAVATAS): a randomized trial. *Stroke*. May 2007; 38(5): 1526-30. PMID 17395869
63. Qureshi AI, Chaudhry SA, Siddiq F, et al. A randomized trial comparing primary angioplasty versus stent placement for symptomatic intracranial stenosis. *J Vasc Interv Neurol*. Dec 2013; 6(2): 34-41. PMID 24358415
64. Alexander MJ, Zauner A, Chaloupka JC, et al. WEAVE Trial: Final Results in 152 On-Label Patients. *Stroke*. Apr 2019; 50(4): 889-894. PMID 31125298
65. Food and Drug Administration. FDA Executive Summary General Issues: Meeting to Discuss the Evaluation of Safety and Effectiveness of Endovascular Medical Devices Intended to Treat Intracranial Aneurysms. <https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/NeurologicalDevicesPanel/UCM598459.pdf>. Accessed March 3, 2022.
66. Hong Y, Wang YJ, Deng Z, et al. Stent-assisted coiling versus coiling in treatment of intracranial aneurysm: a systematic review and meta-analysis. *PLoS One*. 2014; 9(1): e82311. PMID 24454690
67. Ryu CW, Park S, Shin HS, et al. Complications in Stent-Assisted Endovascular Therapy of Ruptured Intracranial Aneurysms and Relevance to Antiplatelet Administration: A Systematic Review. *AJNR Am J Neuroradiol*. Sep 2015; 36(9): 1682-8. PMID 26138136
68. Piotin M, Blanc R, Spelle L, et al. Stent-assisted coiling of intracranial aneurysms: clinical and angiographic results in 216 consecutive aneurysms. *Stroke*. Jan 2010; 41(1): 110-5. PMID 19959540
69. Hetts SW, Turk A, English JD, et al. Stent-assisted coiling versus coiling alone in unruptured intracranial aneurysms in the matrix and platinum science trial: safety, efficacy, and mid-term outcomes. *AJNR Am J Neuroradiol*. Apr 2014; 35(4): 698-705. PMID 24184523
70. Consoli A, Vignoli C, Renieri L, et al. Assisted coiling of saccular wide-necked unruptured intracranial aneurysms: stent versus balloon. *J Neurointerv Surg*. Jan 2016; 8(1): 52-7. PMID 25428449
71. Liu YQ, Wang QJ, Zheng T, et al. Single-centre comparison of procedural complications, clinical outcome, and angiographic follow-up between coiling and stent-assisted coiling for posterior communicating artery aneurysms. *J Clin Neurosci*. Dec 2014; 21(12): 2140-4. PMID 25037315
72. King B, Vaziri S, Singla A, et al. Clinical and angiographic outcomes after stent-assisted coiling of cerebral aneurysms with Enterprise and Neuroform stents: a comparative analysis of the literature. *J Neurointerv Surg*. Dec 2015; 7(12): 905-9. PMID 25352581
73. Geyik S, Yavuz K, Yurtutan N, et al. Stent-assisted coiling in endovascular treatment of 500 consecutive cerebral aneurysms with long-term follow-up. *AJNR Am J Neuroradiol*. Nov-Dec 2013; 34(11): 2157-62. PMID 23886748
74. Lee KM, Jo KI, Jeon P, et al. Predictor and Prognosis of Procedural Rupture during Coil Embolization for Unruptured Intracranial Aneurysm. *J Korean Neurosurg Soc*. Jan 2016; 59(1): 6-10. PMID 26885280
75. Jankowitz BT, Hanel R, Jadhav AP, et al. Neuroform Atlas Stent System for the treatment of intracranial aneurysm: primary results of the Atlas Humanitarian Device Exemption cohort. *J Neurointerv Surg*. Aug 2019; 11(8): 801-806. PMID 30670625
76. Food and Drug Administration (FDA). SUMMARY OF SAFETY AND EFFECTIVENESS DATA (SSED): Neuroform Atlas Stent System (P180031). 2019. https://www.accessdata.fda.gov/cdrh_docs/pdf18/P180031B.pdf Accessed March 9, 2022.
77. Fiorella D, Boulos A, Turk AS, et al. The safety and effectiveness of the LVIS stent system for the treatment of wide-necked cerebral aneurysms: final results of the pivotal US LVIS trial. *J Neurointerv Surg*. Apr 2019; 11(4): 357-361. PMID 30297543
78. Food and Drug Administration (FDA). SUMMARY OF SAFETY AND EFFECTIVENESS DATA (SSED): Low-Profile Visualized Intraluminal Support (LVIS) and LVIS Jr (P170013). 2018. https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170013B.pdf. Accessed March 8, 2022.
79. Feng Z, Fang Y, Xu Y, et al. The safety and efficacy of low profile visualized intraluminal support (LVIS) stents in assisting coil embolization of intracranial saccular aneurysms: a single center experience. *J Neurointerv Surg*. Nov 2016; 8(11): 1192-1196. PMID 26747876
80. Aydin K, Arat A, Sencer S, et al. Stent-Assisted Coiling of Wide-Neck Intracranial Aneurysms Using Low-Profile LEO Baby Stents: Initial and Midterm Results. *AJNR Am J Neuroradiol*. Oct 2015; 36(10): 1934-41. PMID 26021624
81. Chalouhi N, Jabbour P, Starke RM, et al. Endovascular treatment of proximal and distal posterior inferior cerebellar artery aneurysms. *J Neurosurg*. May 2013; 118(5): 991-9. PMID 23350778
82. Chen Z, Yang Y, Miao H, et al. Endovascular treatment for large and giant fusiform aneurysms of the vertebrobasilar arteries. *Clin Imaging*. Mar-Apr 2013; 37(2): 227-31. PMID 23465972
83. Gentric JC, Biondi A, Piotin M, et al. Safety and efficacy of neuroform for treatment of intracranial aneurysms: a prospective, consecutive, French multicentric study. *AJNR Am J Neuroradiol*. Jun-Jul 2013; 34(6): 1203-8. PMID 23348764
84. Johnson AK, Heiferman DM, Lopes DK. Stent-assisted embolization of 100 middle cerebral artery aneurysms. *J Neurosurg*. May 2013; 118(5): 950-5. PMID 23394339
85. Kulcsar Z, Gorick SL, Gizewski ER, et al. Neuroform stent-assisted treatment of intracranial aneurysms: long-term follow-up study of aneurysm recurrence and in-stent stenosis rates. *Neuroradiology*. Mar 2013; 55(4): 459-65. PMID 23358878
86. Food and Drug Administration. PMA P170024: Summary of Safety and Effectiveness (SSED). Intracranial Aneurysm Flow Diverter. 2018. https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170024B.pdf. Accessed March 4, 2022.

87. Raymond J, Gentric JC, Darsaut TE, et al. Flow diversion in the treatment of aneurysms: a randomized care trial and registry. *J Neurosurg.* Sep 2017; 127(3): 454-462. PMID 27813466
88. Kiselev R, Orlov K, Dubovoy A, et al. Flow diversion versus parent artery occlusion with bypass in the treatment of complex intracranial aneurysms: Immediate and short-term outcomes of the randomized trial. *Clin Neurol Neurosurg.* Sep 2018; 172: 183-189. PMID 30053620
89. Zhou G, Zhu YQ, Su M, et al. Flow-Diverting Devices versus Coil Embolization for Intracranial Aneurysms: A Systematic Literature Review and Meta-analysis. *World Neurosurg.* Apr 2016; 88: 640-645. PMID 26585732
90. Xin WQ, Xin QQ, Yuan Y, et al. Comparison of Flow Diversion and Coiling for the Treatment of Unruptured Intracranial Aneurysms. *World Neurosurg.* Aug 2019; 128: 464-472. PMID 31132489
91. English JD, Yavagal DR, Gupta R, et al. Mechanical Thrombectomy-Ready Comprehensive Stroke Center Requirements and Endovascular Stroke Systems of Care: Recommendations from the Endovascular Stroke Standards Committee of the Society of Vascular and Interventional Neurology (SVIN). *Interv Neurol.* Mar 2016; 4(3-4): 138-50. PMID 27051410
92. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke.* Mar 2018; 49(3): e46-e110. PMID 29367334
93. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke.* Dec 2019; 50(12): e344-e418. PMID 31662037
94. Thompson BG, Brown RD, Amin-Hanjani S, et al. Guidelines for the Management of Patients With Unruptured Intracranial Aneurysms: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke.* Aug 2015; 46(8): 2368-400. PMID 26089327
95. Center for Medicare & Medicaid Services. Decision Memo for Intracranial Stenting and Angioplasty (CAG- 00085R5). 2008; <https://www.cms.gov/medicare-coverage-database/details/nca-proposed-decision-memo.aspx?NCAId=214&fromdb=true>. Accessed March 8, 2022.

POLICY HISTORY - THIS POLICY WAS APPROVED BY THE FEP® PHARMACY AND MEDICAL POLICY COMMITTEE ACCORDING TO THE HISTORY BELOW:

Date	Action	Description
December 2011	New policy	
December 2012	Replace policy	Rationale and references updated with literature review. No change to policy.
September 2013	Replace policy	Policy updated with literature review, References 4-7 added. Editorial revisions made to rationale. No change to policy statements.
March 2014	Replace policy	Policy Background and Rationale sections extensively revised and reorganized to incorporate indications and devices previously included in policy 2.01.76 Mechanical Embolectomy for Treatment of Acute Stroke (Archived). Policy updated with literature review through adding reference numbers 1, 3-5, 11, 13-16, 43-51, 56, 60, 67, 70-84 and 86-88. Policy statement from 2.01.76 added; no other change to policy statements.
September 2014	Replace policy	Policy statement added to provide clarity for medically necessary intent for FDA approved devices and their intended uses. No new references
March 2015	Replace policy	Policy updated with literature review through December 12, 2014. References 3-5, 9, 13-14, 19-20, 30-31, 38-39, 54-61, 69, 75-78, 82, 86, 90, 95-96, 106, and 109-111 added. Language added to policy guidelines to specify that policy statements do not apply to endovascular interventions to treat cerebral ischemia resulting from vasospasm after aneurysmal subarachnoid hemorrhage. Policy statements otherwise unchanged.
December 2016	Replace policy	Policy updated with literature review. References 6, 12, 21-27, 32, 39, 44-45, 84, 98, 109, 112, 116, 120-123, 128, 130, 135- 136, and 138-141 added. Policy statements unchanged.
December 2017	Replace policy	Policy updated with literature review through July 21, 2017; reference 148 added. Policy statements unchanged except "not medically necessary" corrected to "investigational."
June 2018	Replace policy	Policy updated with literature review through February 5, 2018; references 9-10, 40-44, 53, 113, and 135-136 added. Policy statements changed to reflect extension of the time window for mechanical thrombectomy up to 24 hours after symptom onset for select patients.
June 2019	Replace policy	Policy updated with literature review through February 7, 2019; multiple references removed; references added. Policy statements unchanged.
June 2020	Replace policy	Policy updated with literature review through February 18, 2020; references added. Policy statements unchanged.
June 2021	Replace policy	Policy updated with literature review through March 11, 2021; references added. Policy statements unchanged.
June 2022	Replace policy	Policy updated with literature review through March 2, 2022; references added. Policy statements unchanged.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.